The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized controlled trial comparing modified gemcitabine plus oxaliplatin (mGEMOX) to gemcitabine plus cisplatin in management of unresectable gall bladder cancer.
Atul Sharma
No relevant relationships to disclose
Surendra Pal Chaudhary
No relevant relationships to disclose
N. K. Shukla
No relevant relationships to disclose
BK Mohanti
No relevant relationships to disclose
S. V. S. Deo
No relevant relationships to disclose
Sujoy Pal
No relevant relationships to disclose
Sanjay Thulkar
No relevant relationships to disclose
Sreenivas Vishnubhatla
No relevant relationships to disclose
Rakesh Kumar
No relevant relationships to disclose
Venkateswaran K Iyer
No relevant relationships to disclose
Vinod Raina
No relevant relationships to disclose